Medical Research
Analysis
Pooled Analysis Confirms Beta-Blockers Can Be Safely Discontinued in Stable Post-Heart Attack Patients
7 sources · 2d ago
Explainer
Pan-KRAS Inhibitor Daraxonrasib Shrinks Tumors in 30% of Metastatic Lung Cancer Patients
6 sources · 14h ago
Explainer
Decoding Medical Statistics: Why Relative Risk Reduction Overstates Treatment Benefits
9 sources · 4d ago
More in Medical Research
AnalysisLeukemia Treatment
Less-Intensive Drug Combination Outperforms Standard Chemotherapy in Acute Myeloid Leukemia Trial
Clinical Researchers 40%Patient Quality-of-Life Advocates 35%Standard-of-Care Proponents 25%
6 sources · 3d ago
ExplainerAlexander Disease
FDA Approves First Disease-Modifying Drug for Rare Neurological Disorder Alexander Disease
Clinical Neurologists 40%Pharmacy & Logistics Teams 30%Patient Families 30%
6 sources · 2d ago
AnalysisVaccine Tech
GSK's mRNA Flu Vaccine Beats Standard Shots in Phase 2, Advances to Phase 3 Trials
Public Health Advocates 40%Biotech Industry Analysts 30%Clinical Practitioners 30%
7 sources · 4d ago
AnalysisCeliac Disease
Teva's Anti-IL-15 Antibody Halts Intestinal Damage in Phase 2a Celiac Trial
Patient Advocacy Groups 40%Conservative Gastroenterologists 30%Pharmaceutical Developers 30%
7 sources · 1d ago
AnalysisSleep Apnea
Once-Nightly Pill Cuts Sleep Apnea Interruptions by 44% in Phase 3 Trial
Clinical Pragmatists 60%Traditional Sleep Specialists 40%
2 sources · 5d ago
ExplainerMultiple Sclerosis
Oral BTK Inhibitor Remibrutinib Shows Superiority in Phase 3 Multiple Sclerosis Trials
Clinical Researchers 40%Pharmaceutical Industry 35%Patient Advocates 25%
6 sources · 5d ago
Essential ThrombocythemiaTreatment Breakthrough
FDA Approves First Essential Thrombocythemia Drug in 30 Years, Targeting Underlying Disease
Clinical Hematologists 45%Patient Advocacy Groups 35%Oncology Nursing Community 20%
6 sources · 6d ago
AnalysisCardiology Research
PCSK9 Inhibitor Repatha Cuts All-Cause Death Risk by 20% in High-Risk Primary Prevention Patients
Clinical Researchers 50%Industry Analysts 30%Factlen Editorial Team 20%
5 sources · 6d ago
ExplainerCardiovascular Health
The Biological Mechanism of Heart Attacks: Why Inflammation is as Dangerous as Cholesterol
Inflammation-First Cardiologists 40%Traditional Lipidologists 40%Environmental Health Advocates 20%
8 sources · 9d ago
ExplainerDietary Sweeteners
Common Sweetener Xylitol Linked to 57% Higher Risk of Heart Attack and Stroke in Landmark Study
Cardiovascular Researchers 40%Public Health Advocates 40%Dental Professionals 20%
4 sources · 9d ago
ExplainerCardiovascular Health
FDA Approves Mounjaro to Reduce Heart Attack and Stroke Risk in Type 2 Diabetes Patients
Medical Consensus 50%Industry Analysts 30%Clinical Practitioners 20%
5 sources · 7d ago
Research BriefLiver Disease
Clinical Trial Finds Keto Diet Cuts Liver Fat by 67%, Outperforming Mediterranean Diet for MASLD
Clinical Researchers 40%Public Health Advocates 30%General Wellness Observers 30%
7 sources · 8d ago
ExplainerPolycythemia Vera
FDA Approves Mimrylo as First-in-Class Treatment for Rare Blood Cancer Polycythemia Vera
Clinical Hematologists 40%Industry Analysts 30%Drug Developers 30%
6 sources · 9d ago
AnalysisGene Therapy
Single-Dose CRISPR Gene Therapy Safely Lowers LDL Cholesterol by 52.5% After One Year in Phase 1 Trial
Clinical Researchers 40%Therapeutics Developers 30%Patient Care Advocates 30%
6 sources · 7d ago
ExplainerGenetic Medicine
Engineered tRNA Therapeutic Could Treat Thousands of Genetic Diseases by Correcting Nonsense Mutations
Genetic Medicine Researchers 40%Biotech Industry Analysts 35%tRNA Therapeutics Developers 25%
4 sources · 11d ago
AnalysisAutoimmune Breakthrough
CAR T-Cell Therapy Successfully Reverses Severe Rheumatoid Arthritis in Landmark Study
Clinical Researchers 40%Rheumatology Specialists 35%Patient Advocates 25%
3 sources · 10d ago
Blindspot
Important stories the mainstream barely covered
High-impact news with only 1–3 outlets covering it. These stories matter — they just didn't make the radar.